Chronic Kidney Disease(CKD) — Medication Adherence Given Individual SystemCHANGE(TM) in Advancing Nephropathy (MAGICIAN) Pilot Study
Citation(s)
Alemi F, Neuhauswer D A thinking person's step by step guide to changing your lifestyle: Weight loss and exercise program. . Victoria, Canada: Trafford Publishing. 2005.
Bowling A Just one question: If one question works, why ask several? J Epidemiol Community Health. 2005 May;59(5):342-5. doi: 10.1136/jech.2004.021204. No abstract available.
Bronfenbrenner U The ecology of human development: Experiments by design and nature. In: Cambridge, MA: Harvard University Press; 1979.
Bronfenbrenner U Toward an experimental ecology of human development. American psychologist. 1977;32(7):513.
Callahan CM, Unverzagt FW, Hui SL, Perkins AJ, Hendrie HC Six-item screener to identify cognitive impairment among potential subjects for clinical research. Med Care. 2002 Sep;40(9):771-81. doi: 10.1097/00005650-200209000-00007.
Conn VS, Ruppar TM, Enriquez M, Cooper P Medication adherence interventions that target subjects with adherence problems: Systematic review and meta-analysis. Res Social Adm Pharm. 2016 Mar-Apr;12(2):218-46. doi: 10.1016/j.sapharm.2015.06.001. Epub 2015 Jun 15.
Debella YT, Giduma HD, Light RP, Agarwal R Chronic kidney disease as a coronary disease equivalent--a comparison with diabetes over a decade. Clin J Am Soc Nephrol. 2011 Jun;6(6):1385-92. doi: 10.2215/CJN.10271110. Epub 2011 Mar 10.
Deming E , Orsini J. The Essential Deming: Leadership Principles from the Father of Quality. New York, NY: McGraw-Hill Education; 2012.
Denhaerynck K, Schafer-Keller P, Young J, Steiger J, Bock A, De Geest S Examining assumptions regarding valid electronic monitoring of medication therapy: development of a validation framework and its application on a European sample of kidney transplant patients. BMC Med Res Methodol. 2008 Feb 19;8:5. doi: 10.1186/1471-2288-8-5.
Devilly GJ, Borkovec TD Psychometric properties of the credibility/expectancy questionnaire. J Behav Ther Exp Psychiatry. 2000 Jun;31(2):73-86. doi: 10.1016/s0005-7916(00)00012-4.
Easthall C, Song F, Bhattacharya D A meta-analysis of cognitive-based behaviour change techniques as interventions to improve medication adherence. BMJ Open. 2013 Aug 9;3(8):e002749. doi: 10.1136/bmjopen-2013-002749. Erratum In: BMJ Open. 2014;4(7). doi: 10.1136/bmjopen-2013-002749corr1.
Evans M, Bain SC, Hogan S, Bilous RW; Collaborative Study Group participants Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. Nephrol Dial Transplant. 2012 Jun;27(6):2255-63. doi: 10.1093/ndt/gfr696. Epub 2011 Dec 15.
Finitsis DJ, Pellowski JA, Johnson BT Text message intervention designs to promote adherence to antiretroviral therapy (ART): a meta-analysis of randomized controlled trials. PLoS One. 2014 Feb 5;9(2):e88166. doi: 10.1371/journal.pone.0088166. eCollection 2014.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004 Sep 23;351(13):1296-305. doi: 10.1056/NEJMoa041031. Erratum In: N Engl J Med. 2008;18(4):4.
Hertzog MA Considerations in determining sample size for pilot studies. Res Nurs Health. 2008 Apr;31(2):180-91. doi: 10.1002/nur.20247.
Horvath T, Azman H, Kennedy GE, Rutherford GW Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection. Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD009756. doi: 10.1002/14651858.CD009756.
Karamanidou C, Clatworthy J, Weinman J, Horne R A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol. 2008 Jan 31;9:2. doi: 10.1186/1471-2369-9-2.
Magacho EJ, Ribeiro LC, Chaoubah A, Bastos MG Adherence to drug therapy in kidney disease. Braz J Med Biol Res. 2011 Mar;44(3):258-62. doi: 10.1590/s0100-879x2011007500013. Epub 2011 Feb 4.
Marcum ZA, Sevick MA, Handler SM Medication nonadherence: a diagnosable and treatable medical condition. JAMA. 2013 May 22;309(20):2105-6. doi: 10.1001/jama.2013.4638. No abstract available.
Matteson M, Russell C, Winn J Pilot Intervention to Improve Medication Adherence in Nonadherent Inflammatory Bowel Disease Patients: P-3. Inflammatory Bowel Diseases. 2011;17(Suppl_2):S13-S13.
Moore SM, Jones L, Alemi F Family self-tailoring: Applying a systems approach to improving family healthy living behaviors. Nurs Outlook. 2016 Jul-Aug;64(4):306-311. doi: 10.1016/j.outlook.2016.05.006. Epub 2016 May 18.
Muntner P, Judd SE, Krousel-Wood M, McClellan WM, Safford MM Low medication adherence and hypertension control among adults with CKD: data from the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. Am J Kidney Dis. 2010 Sep;56(3):447-57. doi: 10.1053/j.ajkd.2010.02.348. Epub 2010 May 14.
Radhakrishnan K The efficacy of tailored interventions for self-management outcomes of type 2 diabetes, hypertension or heart disease: a systematic review. J Adv Nurs. 2012 Mar;68(3):496-510. doi: 10.1111/j.1365-2648.2011.05860.x. Epub 2011 Oct 20.
Russell CL, Ruppar TM, Matteson M Improving medication adherence: moving from intention and motivation to a personal systems approach. Nurs Clin North Am. 2011 Sep;46(3):271-81, v. doi: 10.1016/j.cnur.2011.05.004.
Russell CL A clinical nurse specialist-led intervention to enhance medication adherence using the plan-do-check-act cycle for continuous self-improvement. Clin Nurse Spec. 2010 Mar-Apr;24(2):69-75. doi: 10.1097/NUR.0b013e3181cf554d.
Schmitt KE, Edie CF, Laflam P, Simbartl LA, Thakar CV Adherence to antihypertensive agents and blood pressure control in chronic kidney disease. Am J Nephrol. 2010;32(6):541-8. doi: 10.1159/000321688. Epub 2010 Nov 2.
Shimohata H, Maruyama H, Ogawa Y, Kobayashi M Hyperthyroidism associated with obesity-related glomerulopathy-like pathologic features. Intern Med. 2014;53(9):997-9. doi: 10.2169/internalmedicine.53.1814. Epub 2014 May 1.
Shrestha SS, Shakya R, Karmacharya BM, Thapa P Medication adherence to oral hypoglycemic agents among type II diabetic patients and their clinical outcomes with special reference to fasting blood glucose and glycosylated hemoglobin levels. Kathmandu Univ Med J (KUMJ). 2013 Jul-Sep;11(43):226-32. doi: 10.3126/kumj.v11i3.12510.
Tangkiatkumjai M, Walker DM, Praditpornsilpa K, Boardman H Association between medication adherence and clinical outcomes in patients with chronic kidney disease: a prospective cohort study. Clin Exp Nephrol. 2017 Jun;21(3):504-512. doi: 10.1007/s10157-016-1312-6. Epub 2016 Jul 20.
Williams A, Manias E, Liew D, Gock H, Gorelik A Working with CALD groups: testing the feasibility of an intervention to improve medication self- management in people with kidney disease, diabetes, and cardiovascular disease. Renal Society of Australasia
Williams A, Manias E, Walker R, Gorelik A A multifactorial intervention to improve blood pressure control in co-existing diabetes and kidney disease: a feasibility randomized controlled trial. J Adv Nurs. 2012 Nov;68(11):2515-25. doi: 10.1111/j.1365-2648.2012.05950.x. Epub 2012 Feb 15.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.